Recobia Therapeutics

Make biotherapies accessible to everyone, everywhere

Revolutionizing subcutaneous administration of antibodies

RecoGel polymeric platform can convert any antibody intravenous (IV) formulation into a formulation for subcutaneous administration. RecoGel is a polysaccharide-based hydrogel, that can be co-formulated with antibodies at high concentration. After subcutaneous injection, RecoGel, loaded with the antibodies, will form a hydrogel in physiological conditions, allowing the controlled release of antibodies.

An unique hydrogel platform for subcutaneous delivery of antibodies

Simple conversion from IV to SC

High dose, up to 200 mg/mL (almost 2x greater concentration level versus standard SC formulation)

Compatibility across various antibodies

Biocompatible formulation

Biodegradable hydrogel

Controlled and tunable release of the antibody

PATIENTS
Better quality of life and mobility

HEALTHCARE PROFESSIONALS
Time savings and better use of dedicated staff

HOSPITALS/PAYERS
Reduced medical resource utilization and treatment costs

PHARMACEUTICAL INDUSTRY
Competitive advantage with a cutting edge delivery platform

Benefits address the full value chain

Many biological drugs are currently administered via intravenous infusion, which are burdensome for both patients and healthcare professionals. 

Recobia Therapeutics wants to offer a better alternative to patients thanks to subcutaneous formulations and intends to alleviate their treatment burden with a faster and less painful administration.

Expanding access to subcutaneous formulations would also streamline healthcare professionals’ time and lower treatment costs, thereby improving treatment accessibility for a larger population.

Discover our pipeline

Molecule
Therapeutic application		 Discovery Pre-clinical Phase 1
Clinical trial		 Phase 2
Clinical trial		 Phase 3
Clinical trial
Monoclonal
Antibodies
 Trastuzumab
Breast cancer
Rituximab
Lymphoma
Undisclosed
Colorectal cancer
Undisclosed
Myeloma
Combination
of Antibodies
 Trastuzumab
+ Pertuzumab
Breast cancer
Antibody-Drug
Conjugates
 Undisclosed
Breast cancer
Undisclosed
Breast cancer
Undisclosed
Breast cancer
Monoclonal Antibodies : Trastuzumab (Breast cancer) : Pre-clinical - 100% Rituximab (Lymphoma) : Pre-clinical - 50% Undisclosed (Colorectal cancer) : Discovery - 100% Undisclosed (Myeloma) : Discovery - 100% Combination of Antibodies : Trastuzumab + Pertuzumab (Breast cancer) : Pre-clinical - 30% Antibody-Drug Conjugates : Undisclosed (Breast cancer) : Discovery - 15% Undisclosed (Breast cancer) : Discovery - 10% Undisclosed (Breast cancer) : Discovery - 10%
Scroll to top